Amylyx Pharmaceuticals Inc. (AMLX) reported a net loss of $144.7 million for 2025, with earnings per share of $‑1.53 for the full year and $‑0.30 for the fourth quarter. Cash, cash equivalents and short‑term investments stood at $317 million as of December 31, 2025, down from $344 million at the end of September. Total operating expenses for the year were $153.3 million, a 29% decline from $218.4 million in 2024, driven by a reduction in research and development spending and a sharper cut in selling, general and administrative costs after the company discontinued its ALS program, RELYVRIO.
The 2025 loss represents a significant improvement over the prior year, when the company posted a $301.7 million net loss and a $37.5 million loss in the fourth quarter of 2024. The decline in operating expenses reflects a strategic shift away from the discontinued RELYVRIO ALS program, which generated $380.8 million in net product revenue in 2023 but was halted in April 2024. By reallocating resources toward the avexitide pipeline, Amylyx has tightened its cost base while maintaining a robust cash position that extends into 2028.
Enrollment for the pivotal Phase 3 LUCIDITY trial of avexitide in post‑bariatric hypoglycemia (PBH) is now complete. Management expects topline data in the third quarter of 2026 and is preparing for a potential FDA submission and commercial launch in 2027. The company’s cash runway, combined with disciplined spending, positions it to fund the remaining clinical development without immediate dilution risk.
"2025 was a year of meaningful advancement for Amylyx’s pivotal avexitide program in post‑bariatric hypoglycemia, as well as progress across our broader pipeline," said Co‑CEOs Joshua Cohen and Justin Klee. "In 2026, our primary focus is on our Phase 3 LUCIDITY trial of avexitide in PBH. With recruitment of LUCIDITY complete, we are on track to complete enrollment this month and continue to expect topline data in Q3 2026. Looking ahead, we have a clear trajectory toward potentially delivering the first FDA‑approved therapy to the PBH community. Supported by a cash runway extending into 2028, we remain focused on disciplined execution as we continue to actively prepare for a regulatory submission and build our commercial infrastructure to support potential commercialization in 2027."
The earnings beat analyst expectations by $0.24 per share, largely due to the company’s aggressive cost‑control measures and the absence of revenue in 2025. The reduction in operating expenses, coupled with a stable cash balance, underscores Amylyx’s ability to sustain its clinical program while avoiding the need for immediate capital raises. The company’s focus on a single, high‑potential asset—avexitide—positions it to capture a $1–$3 billion market opportunity in PBH, while its disciplined financial management mitigates the risk of future dilution. The lack of revenue in 2025 reflects the pre‑revenue nature of the business, but the company’s strategic pivot and strong cash position provide a solid foundation for the upcoming clinical milestones.
The company has not issued new guidance for 2026 or beyond, but the management commentary signals confidence in meeting the planned clinical timelines and maintaining its cash runway. Investors will likely view the company’s disciplined cost structure and clear pipeline focus as positive indicators for future performance, despite the current pre‑revenue status.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.